Hoatlin Lab: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
(119 intermediate revisions by 5 users not shown)
Line 1: Line 1:
=Welcome to the Hoatlin Lab Wiki=
{{HoatlinLab}}


Our lab is interested in understanding how the [http://www.fanconi.org/ Fanconi anemia] proteins contribute to genomic stability with the goal of developing drugs that will help Fanconi patients and those who are susceptible to developing cancer.
<div style="padding: 15px; width: 710px; border: 5px solid #B3CD4E;">
We work in [[Hoatlin:Portland Oregon| Portland, Oregon]] at [http://www.ohsu.edu/ OHSU], in the [http://www.ohsu.edu/biochem/ Department of Biochemistry & Molecular Biology]. Our Departmental web pages (not updated wiki-frequently) can be viewed [http://www.ohsu.edu/research/hoatlin/ here (web page)] and [http://www.ohsu.edu/biochem/faculty/faculty.cfm?facultyID=29 here (faculty page)].
<div style="padding: 1px; width: 700px; border: 3px solid #DDDDFF;">


We hope that other Fanconi labs will join us at [http://openwetware.org/wiki/ OpenWetWare] because it might help FA research go faster, stimulate collaborative efforts, facilitate reagent distribution, and expand communication. We also believe that an understanding of the complex and enigmatic Fanconi anemia protein network could benefit from the attention of systems/synthetic biologists already on OWW.  
<div style="border:1px solid orange;background-color:#FFFACD;padding:1px;">
----
'''Lab News'''
;For news, follow the [http://twitter.com/HoatlinLab Hoatlin lab Twitter]
</div>
<br>
Our laboratory is interested in understanding the molecular function of the Fanconi anemia (FA) protein network in context with other proteins that regulate or influence genomic stability. Fanconi anemia is a rare genetic disease that is typically associated with developmental abnormalities, bone marrow failure and increased risk of cancer. Because the majority of the FA proteins are unique with no significant homologies, we expect the results of our studies to shed new light on fundamental mechanisms that control the integrity of the human genome and influence cancer susceptibility. The FA pathway is part of a network of proteins that contains BRCA2 and two other recently identified FA genes (FANCN and FANCJ) that influence breast cancer susceptibility.  Ultimately, insights into the mechanism of the FA/BRCA network of proteins will lead to an understanding of the underlying molecular defect in FA and may lead to more effective avenues of treatment for this devastating pediatric disease and cancer.  


[[Image:Labphoto.jpg|right|frame|[[Hoatlin:Research Team|Research Team, minus Victor]]]]
We work in [[Hoatlin:Portland Oregon| Portland, Oregon]] at [http://www.ohsu.edu/ OHSU], in the [http://www.ohsu.edu/biochem/ Department of Biochemistry & Molecular Biology] and the [http://www.ohsucancer.com/ OHSU Knight Cancer Institute].
*[[Hoatlin:Research Interests|Research Interests]]
*[[Hoatlin:Research Team|Research Team]]
*[[Hoatlin:Publications|Publications]]
*[[Hoatlin:Projects|Projects]]
*[[Hoatlin:Collaborations|Collaborations]]
*[[Hoatlin:Reagent Requests|Reagent Requests]]
*[[Hoatlin:Protocols|Standard Protocols]]
*[[Hoatlin:Contact Info|Contact Info & Directions]]
*[[Hoatlin:Contribute|Contribute to FA Research]]
*[[Hoatlin:News|Hoatlin Lab News]]
*[[Hoatlin: View from our Lab|Our View]]
*[[Hoatlin:Internal Lab Site|The Back Door]]


=OHSU DNA R3 Club=
==Bio for Maureen Hoatlin==
Topic selection and meeting schedules for 2006-2007 are now in progress for the [[Hoatlin:OHSU Replication, Recombination and Repair (R3) Club|OHSU DNA Replication, Recombination and Repair (R3) Club]].
=BMB Seminar Series=
[[Hoatlin:BMB Seminar Series| BMB Seminar Series planning]] in progress for 2006-2007.
=Courses and Curriculum Development=
A Special Topics course in the Department of Biochemistry and Molecular Biology is under discussion.  Please add to the


[[Hoatlin:Courses and Curriculum Development|Course Development Discussion]]
Maureen Hoatlin is an Associate Professor of Biochemistry & Molecular Biology, and Molecular & Medical Genetics at Oregon Health & Science University (OHSU).  After earning a B.S. degree in Chemistry from Old Dominion University, she was a project chemist at SRI International in Menlo Park, CA for two years, followed by six years as a research associate at Genentech, Inc. She received a Ph.D. at Oregon Health & Science University for graduate work focusing on the role of retroviruses in pathogenesis and hematopoietic cancers.  She joined the faculty in Hematology & Medical Oncology at OHSU in 1993, and was a Visiting Scientist & Professor in the Department of Genetics at the Free University and Medical Center of Amsterdam in 1998 and in 2002.  Dr. Hoatlin’s research is focused on identifying and analyzing the function of the proteins in the Fanconi Anemia/Breast Cancer (FA/BRCA) cancer susceptibility pathway.  Her work has contributed to the discovery and characterization of ten novel human genes, many with critical but poorly understood roles in hematopoiesis, cancer susceptibility (AML and other cancers), and resistance to certain commonly-used chemotherapeutic drugs. Dr. Hoatlin’s lab pioneered a cell-free approach to analyze the function of the FA/BRCA pathway and recently received a patent for a novel small molecule inhibitor screen for identification of FA/BRCA pathway inhibitors and potential chemosensitizing compounds.


Dr. Hoatlin has recently completed an MBA with a specialty on international business in Asia, as well a specialized UCSF course (ACDRS) on the drug development pipeline that focuses on preparation for future developments and changes in the global pharmaceutical sector. Dr. Hoatlin is a member of the strategic planning leadership for OHSU’s School of Medicine, the Hematologic Malignancies Program, advisory board member of the Oregon Translational Research and Development Institute, and founding co-chair of the OHSU Rare Disease Consortium. Dr. Hoatlin is interested in developing industry-academic partnerships aimed at using rare disease research to de-risk drug development.


==Teaching Links==


''[[Simple_wiki_editing_examples|wiki edit instructions]]
*Our lab's Fanconi Anemia antibodies are available from [http://www.novusbio.com Novus Biologicals] and by Millipore.
 
[http://www.openwetware.org/wiki/Hoatlin:CONJ606/PMCB CONJ606/PMCB]
 
[[Hoatlin:OHSU_Genetic_Mechanisms_Class| Genetic Mechanisms Class (CON662)]]
 
[[Hoatlin: CSF|Med Students Fundamentals]]
 
==Biochemistry Seminar Series==
[http://www.openwetware.org/wiki/Hoatlin:BMB_seminar_series_2017-2018 Biochemistry Seminar Series and Combined Series Working Draft]
 
==Classes of the past==
[[BMCB625|Advanced Topics in Molecular Biology(BMB625)]]
 
[http://openwetware.org/wiki/CANB_610 Advanced Topics in Cancer Biology (CANB 610)]
 
[[Hoatlin:OHSU Replication, Recombination and Repair (R3) Club| OHSU DNA Replication, Recombination and Repair (R3) Club]].
 
==Who is Visiting Us?==
 
'''Who's visiting?'''
 
<html>
<a href="http://clustrmaps.com/counter/maps.php?url=http://openwetware.org/wiki/Hoatlin_Lab" id="clustrMapsLink"><img src="http://clustrmaps.com/counter/index2.php?url=http://openwetware.org/wiki/Hoatlin_Lab" border=1 alt="Locations of visitors to this page"onError="this.onError=null; this.src='http://www.meetomatic.com/images/clustrmaps-back-soon.jpg'; document.getElementById('clustrMapsLink').href='http://clustrmaps.com/'">
</a>
</html>
[[Image:Hoatlinclustermap.jpg]]
 
==Basic Wiki/OWW Links==
 
*[http://openwetware.org/wiki/Help:Contents Help Overview]
 
*[[OpenWetWare:How_to_join | How to join]]
 
*[[OWW.101:OpenWetWare | Using OpenWetWare]]
 
*[[OWW.101:Guidelines for editing OpenWetWare|Guidelines for editing OpenWetWare]]
 
<wikionly>
<font size=4>'''Recent changes'''</font>{{Special:Recentchanges/Hoatlin}}
</wikionly>

Revision as of 11:56, 8 August 2017

Equipped with his five senses, man explores the universe around him and calls the adventure Science. ~Edwin Powell Hubble, The Nature of Science, 1954

Home        Projects        Team        Papers        Contact Us        Protocols        Collaborations        News        Reagent Requests        secret back door        Hoatlin Lab Twitter       



Lab News

For news, follow the Hoatlin lab Twitter


Our laboratory is interested in understanding the molecular function of the Fanconi anemia (FA) protein network in context with other proteins that regulate or influence genomic stability. Fanconi anemia is a rare genetic disease that is typically associated with developmental abnormalities, bone marrow failure and increased risk of cancer. Because the majority of the FA proteins are unique with no significant homologies, we expect the results of our studies to shed new light on fundamental mechanisms that control the integrity of the human genome and influence cancer susceptibility. The FA pathway is part of a network of proteins that contains BRCA2 and two other recently identified FA genes (FANCN and FANCJ) that influence breast cancer susceptibility. Ultimately, insights into the mechanism of the FA/BRCA network of proteins will lead to an understanding of the underlying molecular defect in FA and may lead to more effective avenues of treatment for this devastating pediatric disease and cancer.

We work in Portland, Oregon at OHSU, in the Department of Biochemistry & Molecular Biology and the OHSU Knight Cancer Institute.

Bio for Maureen Hoatlin

Maureen Hoatlin is an Associate Professor of Biochemistry & Molecular Biology, and Molecular & Medical Genetics at Oregon Health & Science University (OHSU). After earning a B.S. degree in Chemistry from Old Dominion University, she was a project chemist at SRI International in Menlo Park, CA for two years, followed by six years as a research associate at Genentech, Inc. She received a Ph.D. at Oregon Health & Science University for graduate work focusing on the role of retroviruses in pathogenesis and hematopoietic cancers. She joined the faculty in Hematology & Medical Oncology at OHSU in 1993, and was a Visiting Scientist & Professor in the Department of Genetics at the Free University and Medical Center of Amsterdam in 1998 and in 2002. Dr. Hoatlin’s research is focused on identifying and analyzing the function of the proteins in the Fanconi Anemia/Breast Cancer (FA/BRCA) cancer susceptibility pathway. Her work has contributed to the discovery and characterization of ten novel human genes, many with critical but poorly understood roles in hematopoiesis, cancer susceptibility (AML and other cancers), and resistance to certain commonly-used chemotherapeutic drugs. Dr. Hoatlin’s lab pioneered a cell-free approach to analyze the function of the FA/BRCA pathway and recently received a patent for a novel small molecule inhibitor screen for identification of FA/BRCA pathway inhibitors and potential chemosensitizing compounds.

Dr. Hoatlin has recently completed an MBA with a specialty on international business in Asia, as well a specialized UCSF course (ACDRS) on the drug development pipeline that focuses on preparation for future developments and changes in the global pharmaceutical sector. Dr. Hoatlin is a member of the strategic planning leadership for OHSU’s School of Medicine, the Hematologic Malignancies Program, advisory board member of the Oregon Translational Research and Development Institute, and founding co-chair of the OHSU Rare Disease Consortium. Dr. Hoatlin is interested in developing industry-academic partnerships aimed at using rare disease research to de-risk drug development.

Teaching Links

  • Our lab's Fanconi Anemia antibodies are available from Novus Biologicals and by Millipore.

CONJ606/PMCB

Genetic Mechanisms Class (CON662)

Med Students Fundamentals

Biochemistry Seminar Series

Biochemistry Seminar Series and Combined Series Working Draft

Classes of the past

Advanced Topics in Molecular Biology(BMB625)

Advanced Topics in Cancer Biology (CANB 610)

OHSU DNA Replication, Recombination and Repair (R3) Club.

Who is Visiting Us?

Who's visiting?

<html> <a href="http://clustrmaps.com/counter/maps.php?url=http://openwetware.org/wiki/Hoatlin_Lab" id="clustrMapsLink"><img src="http://clustrmaps.com/counter/index2.php?url=http://openwetware.org/wiki/Hoatlin_Lab" border=1 alt="Locations of visitors to this page"onError="this.onError=null; this.src='http://www.meetomatic.com/images/clustrmaps-back-soon.jpg'; document.getElementById('clustrMapsLink').href='http://clustrmaps.com/'"> </a> </html>

Basic Wiki/OWW Links

<wikionly>

Recent changes
List of abbreviations:
N
This edit created a new page (also see list of new pages)
m
This is a minor edit
b
This edit was performed by a bot
(±123)
The page size changed by this number of bytes

4 May 2024

     09:20  User:Massih Forootan‎‎ 3 changes history +83 [Massih Forootan‎ (3×)]
     
09:20 (cur | prev) +78 Massih Forootan talk contribs (→‎Link to Publications)
     
09:18 (cur | prev) 0 Massih Forootan talk contribs (→‎Skills)
     
09:18 (cur | prev) +5 Massih Forootan talk contribs (→‎Skills)
     07:28  CHEM-ENG590E:Wiki Textbook‎‎ 4 changes history −445 [Sarah L. Perry‎ (4×)]
     
07:28 (cur | prev) +84 Sarah L. Perry talk contribs (→‎Chapter 4 - Flow Control and Mixing)
     
07:21 (cur | prev) −490 Sarah L. Perry talk contribs (→‎Chapter 9 - Microfluidics and Cell Culture)
     
07:19 (cur | prev) −35 Sarah L. Perry talk contribs (→‎Chapter 9 - Microfluidics and Cell Culture)
     
07:18 (cur | prev) −4 Sarah L. Perry talk contribs (→‎Chapter 4 - Flow Control and Mixing)
     07:18 Move log Sarah L. Perry talk contribs moved page Microfluidic Gradient Generators - Greg Schneider to Microfluidic Gradient Generators(Adding an Author)
     00:15  Renhao Li Lab:Publications diffhist +265 Renhao Li talk contribs (→‎2024)

3 May 2024

     15:02  CHIP:Talks diffhist 0 Gabor Balazsi talk contribs
     15:01  CHIP:Data diffhist −23 Gabor Balazsi talk contribs
     14:33  UA Biophysics:Protocols:Kanamycin‎‎ 5 changes history −421 [Elizabeth Suesca‎ (5×)]
     
14:33 (cur | prev) +13 Elizabeth Suesca talk contribs
     
14:21 (cur | prev) +16 Elizabeth Suesca talk contribs (→‎Materials)
     
14:19 (cur | prev) −6 Elizabeth Suesca talk contribs
     
14:14 (cur | prev) −50 Elizabeth Suesca talk contribs
     
14:13 (cur | prev) −394 Elizabeth Suesca talk contribs
     14:33  UA Biophysics:Protocols:Ampicillin‎‎ 4 changes history −379 [Elizabeth Suesca‎ (4×)]
     
14:33 (cur | prev) +15 Elizabeth Suesca talk contribs
     
14:19 (cur | prev) −7 Elizabeth Suesca talk contribs
     
14:11 (cur | prev) 0 Elizabeth Suesca talk contribs (→‎PROTOCOL)
     
14:09 (cur | prev) −387 Elizabeth Suesca talk contribs
     14:31  UA Biophysics:Protocols:Erythromycin‎‎ 3 changes history −315 [Elizabeth Suesca‎ (3×)]
     
14:31 (cur | prev) −7 Elizabeth Suesca talk contribs
     
14:30 (cur | prev) −12 Elizabeth Suesca talk contribs (→‎Materials)
     
14:18 (cur | prev) −296 Elizabeth Suesca talk contribs
     14:29  UA Biophysics:Protocols:Chloramphenicol‎‎ 2 changes history −427 [Elizabeth Suesca‎ (2×)]
     
14:29 (cur | prev) +36 Elizabeth Suesca talk contribs
     
14:16 (cur | prev) −463 Elizabeth Suesca talk contribs
N    12:09  BioMicroCenter:Oligo Synthesis‎‎ 7 changes history +4,408 [Noelani Kamelamela‎ (7×)]
     
12:09 (cur | prev) −14 Noelani Kamelamela talk contribs (→‎Dr Oligo 96)
     
12:09 (cur | prev) −16 Noelani Kamelamela talk contribs (→‎STX-200)
     
12:08 (cur | prev) −46 Noelani Kamelamela talk contribs (→‎Dr Oligo 96)
     
12:08 (cur | prev) +35 Noelani Kamelamela talk contribs (→‎Dr Oligo 96)
     
08:29 (cur | prev) +7 Noelani Kamelamela talk contribs (→‎Dr Oligo 96)
     
08:27 (cur | prev) +59 Noelani Kamelamela talk contribs (→‎Dr Oligo 96)
N    
08:16 (cur | prev) +4,383 Noelani Kamelamela talk contribs (Created page with "{{BioMicroCenter}} ''' ** All users must be trained before being allowed to use the equipment **'''<BR><BR> The BioMicro Center currently hosts two oligo synthesizers: one Dr Oligo 96 (Biolytic) and one Syntax STX-200 (DNAScript). <br><br> Dr Oligo is optimized for higher concentrations of oligos made through polyamidite synthesis. For ready to use oligos a series of steps must be completed using the other related machines in the Center including the column presser, the...")
     12:06  BioMicroCenter:Covaris‎‎ 5 changes history +172 [Noelani Kamelamela‎ (5×)]
     
12:06 (cur | prev) −5 Noelani Kamelamela talk contribs (→‎R230)
     
09:55 (cur | prev) +2 Noelani Kamelamela talk contribs (→‎R230)
     
09:54 (cur | prev) +1 Noelani Kamelamela talk contribs (→‎R230)
     
09:52 (cur | prev) +4 Noelani Kamelamela talk contribs (→‎R230)
     
08:41 (cur | prev) +170 Noelani Kamelamela talk contribs (→‎R230)
     09:52  (Upload log) [Noelani Kamelamela‎ (6×)]
     
09:52 Noelani Kamelamela talk contribs uploaded File:R230pic.jpg
     
08:42 Noelani Kamelamela talk contribs uploaded File:R230pic.jpeg
     
08:32 Noelani Kamelamela talk contribs uploaded File:Syntax.jpg
     
08:31 Noelani Kamelamela talk contribs uploaded File:Droligoprocess.jpg
     
08:29 Noelani Kamelamela talk contribs uploaded File:Chamber.jpg
     
08:28 Noelani Kamelamela talk contribs uploaded File:DrOligo.jpg

2 May 2024

     19:54  Paper Microfluidic Device for Archiving Breast Epithelial Cells‎‎ 7 changes history −389 [Xning098‎ (7×)]
     
19:54 (cur | prev) −10 Xning098 talk contribs (→‎Diseases tested with neonatal heel pricks)
     
19:53 (cur | prev) −12 Xning098 talk contribs (→‎Results with Breast Epithelial Cells)
     
19:49 (cur | prev) 0 Xning098 talk contribs (→‎Current diagnostic tools)
     
19:45 (cur | prev) +45 Xning098 talk contribs (→‎Design Parameters)
     
19:40 (cur | prev) −412 Xning098 talk contribs (→‎Design Parameters)
     
19:35 (cur | prev) 0 Xning098 talk contribs (→‎Paper Microfluidics)
     
19:32 (cur | prev) 0 Xning098 talk contribs (→‎Possibilities in Breast Cancer Detection)

</wikionly>